Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.44 |
| ▸ | CHUK | O15111 | 11/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446188 | 1.00 | IKBKB (0.44) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5445596 | 0.97 | CA12 (0.44) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5445592 | 0.97 | CA12 (0.44) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5442265 | 0.91 | PRKCQ (0.45) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5442262 | 0.91 | PRKCQ (0.45) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5442125 | 0.89 | PRKCQ (0.42) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5442129 | 0.89 | PRKCQ (0.42) | IKBKBCHUKPRKCQPRKCDSRC | |
| SCHEMBL5442216 | 0.88 | IKBKB (0.44) | IKBKBCHUKSRCCA12ABL1 | |
| SCHEMBL5442212 | 0.88 | IKBKB (0.44) | IKBKBCHUKSRCCA12ABL1 | |
| SCHEMBL14538059 | 0.87 | PRKCQ (0.42) | IKBKBCHUKPRKCQPRKCDSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | IKBKB 204/4885CHUK 32/4885PRKCQ 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.